CIAM
TRVI icon

Caitong International Asset Management’s Trevi Therapeutics TRVI Stock Holding History

Caitong International Asset Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.31K Sell
124
-143
-54% -$2.08K ﹤0.01% 1385
2026
Q1 		$3.19K Sell
267
-3,755
-93% -$42K ﹤0.01% 1172
2025
Q4 		$50.4K Buy
+4,022
New +$46.5K 0.01% 699
2025
Q3 		– Sell
-1,689
Closed -$9.24K – 2527
2025
Q2 		$9.24K Buy
+1,689
New +$10.5K 0.01% 760

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Caitong International Asset Management's TRVI Position: Q2 2026 in Review

Caitong International Asset Management reduced its Trevi Therapeutics (TRVI) stake by 54% in Q2 2026, selling an estimated $2.08K and leaving 124 shares worth $2.31K. The position accounts for ﹤0.01% of the portfolio, ranked #1385.

Caitong International Asset Management first reported a position in TRVI in Q2 2025 and has held it in 4 quarters since. The position peaked at $50.4K in Q4 2025. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Caitong International Asset Management held 124 shares of Trevi Therapeutics worth $2.31K as of Q2 2026.
  • Caitong International Asset Management sold 143 Trevi Therapeutics shares in Q2 2026, an estimated $2.08K.
  • Trevi Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1385 holding.
  • Caitong International Asset Management first reported a position in Trevi Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Caitong International Asset Management's Trevi Therapeutics position peaked at $50.4K in Q4 2025.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.